Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia

Corporate Breaking News

Home : Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia

Aug 27 2018	Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
DUBLIN, Aug. 27, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission approved Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion for the treatment of adults with newly diagnosed, therapy-related acute myeloid...


Source:https://www.prnewswire.com:443/news-releases/vyxeos-receives-marketing-authorisation-in-the-european-union-for-treatment-of-certain-types-of-high-risk-acute-myeloid-leukaemia-300702499.html

Related News
» NetCents Technology unterzeichnet Unternehmenslizenzvereinbarung für 28 karibische Länder und fügt Bitcoin Cash hinzu » Johannesburg Gets Ready for 4th Healthcare Innovation Summit Africa 2018